MX2014014821A - Biomarcadores de plasma sanguineo para terapias de combinacion con bevacizumab para el tratamiento de cancer de mama. - Google Patents

Biomarcadores de plasma sanguineo para terapias de combinacion con bevacizumab para el tratamiento de cancer de mama.

Info

Publication number
MX2014014821A
MX2014014821A MX2014014821A MX2014014821A MX2014014821A MX 2014014821 A MX2014014821 A MX 2014014821A MX 2014014821 A MX2014014821 A MX 2014014821A MX 2014014821 A MX2014014821 A MX 2014014821A MX 2014014821 A MX2014014821 A MX 2014014821A
Authority
MX
Mexico
Prior art keywords
breast cancer
blood plasma
positive breast
treatment
her2 positive
Prior art date
Application number
MX2014014821A
Other languages
English (en)
Spanish (es)
Inventor
Norbert Wild
Ursula Klause
Nicola Moore
Céline Pallaud
Stefan Scherer
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2014014821A publication Critical patent/MX2014014821A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2014014821A 2012-06-26 2013-06-24 Biomarcadores de plasma sanguineo para terapias de combinacion con bevacizumab para el tratamiento de cancer de mama. MX2014014821A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261664612P 2012-06-26 2012-06-26
US201261697667P 2012-09-06 2012-09-06
PCT/EP2013/063094 WO2014001232A1 (en) 2012-06-26 2013-06-24 Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer

Publications (1)

Publication Number Publication Date
MX2014014821A true MX2014014821A (es) 2015-02-12

Family

ID=48672633

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014014821A MX2014014821A (es) 2012-06-26 2013-06-24 Biomarcadores de plasma sanguineo para terapias de combinacion con bevacizumab para el tratamiento de cancer de mama.

Country Status (10)

Country Link
EP (1) EP2864788A1 (ja)
JP (1) JP2015522815A (ja)
KR (1) KR20150024342A (ja)
CN (1) CN104364655A (ja)
BR (1) BR112014032456A2 (ja)
CA (1) CA2871385A1 (ja)
HK (1) HK1202334A1 (ja)
MX (1) MX2014014821A (ja)
RU (1) RU2015102026A (ja)
WO (1) WO2014001232A1 (ja)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3594365A4 (en) * 2017-03-08 2021-01-06 Industry - University Cooperation Foundation Hanyang University HER2-POSITIVE CANCER BIOMARKER AND ANTI-HER2 TREATMENT AND ITS USE
KR102028703B1 (ko) * 2017-11-21 2019-10-04 한양대학교 산학협력단 유방암의 진단 및 치료를 위한 바이오 마커

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0171407B1 (en) 1984-01-30 1993-11-18 Imperial Cancer Research Technology Limited Improvements relating to growth factors
US5401638A (en) 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5081034A (en) 1988-11-14 1992-01-14 Brigham & Women's Hospital Cloned genes which encode elam-1
WO1991005264A1 (en) 1989-09-29 1991-04-18 Oncogenetics Partners Detection and quantification of neu related proteins in the biological fluids of humans
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
US5635388A (en) 1994-04-04 1997-06-03 Genentech, Inc. Agonist antibodies against the flk2/flt3 receptor and uses thereof
US5994071A (en) 1997-04-04 1999-11-30 Albany Medical College Assessment of prostate cancer
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
DE19806989A1 (de) 1998-02-19 1999-08-26 Roche Diagnostics Gmbh Erzeugung räumlich scharf begrenzter Festphasen für Bindungsassays
US6833349B2 (en) * 1999-06-08 2004-12-21 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory skin diseases
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
DE102004029909A1 (de) 2004-06-21 2006-01-19 Roche Diagnostics Gmbh Verfahren und Vorrichtung zur Herstellung von bindungsfähigen Reagenzträgern
RU2010123381A (ru) * 2007-11-09 2011-12-20 Дженентек, Инк. (Us) Способ и композиции для диагностического применения у раковых пациентов
CA2717489A1 (en) * 2008-02-29 2009-09-24 Shinshu University Kit for detecting cancer cells metastasizing into sentinel lymph node
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
US20100029491A1 (en) * 2008-07-11 2010-02-04 Maike Schmidt Methods and compositions for diagnostic use for tumor treatment
BR112012000735A2 (pt) * 2009-07-13 2016-11-16 Genentech Inc "métodos, kits e conjuntos de compostos"
CA2770321A1 (en) * 2009-08-14 2011-02-17 Genentech, Inc. Biological markers for monitoring patient response to vegf antagonists
AU2011205343B2 (en) * 2010-01-12 2015-08-13 Nestec S.A. Methods for predicting response of triple-negative breast cancer to therapy
CN104965084B (zh) * 2010-07-19 2017-09-29 霍夫曼-拉罗奇有限公司 鉴定响应抗癌疗法的可能性升高的患者的方法

Also Published As

Publication number Publication date
EP2864788A1 (en) 2015-04-29
WO2014001232A1 (en) 2014-01-03
KR20150024342A (ko) 2015-03-06
JP2015522815A (ja) 2015-08-06
RU2015102026A (ru) 2016-08-10
CN104364655A (zh) 2015-02-18
HK1202334A1 (en) 2015-09-25
CA2871385A1 (en) 2014-01-03
BR112014032456A2 (pt) 2017-06-27

Similar Documents

Publication Publication Date Title
MX343801B (es) Biomarcadores de plasma de sangre para terapias de combinacion con bevacizumab para tratamiento de cancer de mama.
MX2012007940A (es) Biomarcadores basados en tejido tumoral para terapias combinadas con bevacizumab.
AR089067A1 (es) Biomarcadores en el plasma sanguineo para terapias de combinacion de bevacizumab destinadas al tratamiento del cancer de mama
MX339427B (es) Biomarcadores de plasma de sangre para terapias de combinacion con bevacizumab para tratamiento de cancer pancreatico.
UA114277C2 (uk) Антиангіогенна терапія для лікування раку яєчника
MX2013002084A (es) Biomarcadores y metodos de tratamiento.
MX2021010672A (es) Uso de un anticuerpo que tiene la capacidad para ligarse a clnd6 en el tratamiento o prevención de cáncer.
PT2766040T (pt) Pertuzumab, trastuzumab, docetaxel e carboplatina para o tratamento do cancro da mama em fase precoce
EA201301265A1 (ru) Способ лечения солидных злокачественных опухолей, включая прогрессирующие или метастатические солидные злокачественные опухоли
SG10201903658QA (en) Personalized anti-cancer agent screening system
EA201301269A1 (ru) Способ лечения прогрессирующих солидных опухолей
MX2015012444A (es) Metodos de diagnostico, seleccion y tratamiento de enfermedades y afecciones provocadas por o asociadas con metanogenos.
PH12015500388A1 (en) Cancer diagnostic and therapeutic method targeting molecules expressed in cancer stem cells
BR112014018374A8 (pt) Método para predizer a resposta d eum paciente com câncer, kit, anticorpo, método para o tratamento do câncer e composição farmacêutica
MX2014014821A (es) Biomarcadores de plasma sanguineo para terapias de combinacion con bevacizumab para el tratamiento de cancer de mama.
NZ717595A (en) Methods and tools relating to the administration of contrast medium
WO2012145399A3 (en) Methods of diagnosing cancer in a patient
WO2013171777A3 (en) Use of trop-2 as predictive marker of response to anti-tumor therapy based on inhibitors of cd9, akt and molecules of the tetraspanin signalling network
NZ704554A (en) Combination therapy of a smac mimetic and gm-csf
WO2015036643A3 (es) Marcador para predecir metástasis del cáncer de mama
WO2012019125A3 (en) Biomarkers for prostate cancer and methods for their detection
MX2014014829A (es) Anticuerpos autoinmunes.
UA84044U (ru) Способ прогнозирования чувствительности к неоадьювантной терапии у больных раком молочной железы
IN2014CN02496A (ja)
NZ700301A (en) Tumor tissue based biomarkers for bevacizumab combination therapies